Biologics: The Growth Engine In Advanced Wound Care
Executive Summary
With estimated revenues in excess of $5 billion per year worldwide, the advanced wound care market has garnered the attention of both major companies and investors for its tremendous potential. Growth in this market is being driven by the development of new bioactive products that can successfully heal chronic wounds such as diabetic foot ulcers, which are among the most challenging and costly to treat. This article is reprinted from the June issue of Medtech Insight.
You may also be interested in...
New Irritable Bowel Disease And Burn Therapies Among Those Recommended By Europe’s CHMP
Bayer’s aflibercept, Leo’s ingenol mebutate, Almirall’s linaclotide and a proteolytic enzyme concentrate, Teva’s NexoBrid, were given positive opinions on their marketing by CHMP on Sept. 21, with Almirall taking a different approach to linaclotide’s development than that taken in the U.S.
The Rebirth of Dermagraft
Dermagraft is often mentioned as an example of a failure in tissue engineering, illustrating the difficulty of achieving return on investment in this field. The product was only a market failure, however; clinicians say that it worked to heal difficult wounds, and that it was just a product ahead of its time. Now small company Advanced BioHealing has given new life to the bioengineered dermal substitute, abandoned by Smith & Nephew, by supporting it with the focus, and the unique marketing and manufacturing skills that tissue-engineered products require. In the process, it believes it has created assets and skill-sets from which other tissue-engineering start-ups might benefit.
Novartis’s ‘Poster Child’ Zolgensma Shows What Gene Therapy Can Do – And Its Limitations
The clinical development head of Novartis Gene Therapies talks about the progress for SMA patients more than seven years after treatment began, and hopes of boosting outcomes by treating pre-symptomatic patients.